您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Obinutuzumab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Obinutuzumab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:949142-50-1
包装与价格:
包装价格(元)
1mg电议
5mg电议
25mg电议
50mg电议
100mg电议
200mg电议

产品名称
奥滨尤妥珠单抗
GA101
Anti-Human CD20 type II, Humanized Antibody
产品介绍
Obinutuzumab (GA101) 是新型糖工程化 II 型 CD20 人源化 IgG1 单克隆抗体,用于非霍奇金淋巴瘤的研究。
生物活性

Obinutuzumab (GA101) a novel glycoengineered Type IICD20humanizedIgG1monoclonal antibody in development for non-Hodgkin lymphoma.

体外研究
(In Vitro)

Obinutuzumab is found to be superior to rituximab and ofatumumab in the induction of direct cell death (independent of mechanical manipulation required for cell aggregate disruption formed by antibody treatment), whereas it is 10 to 1,000 times less potent in mediating CDC. Obinutuzumab shows superior activity to rituximab and ofatumumab in ADCC and whole-blood B-cell depletion assays, and is comparable with these two in ADCP. Obinutuzumab also shows slower internalization rate upon binding to CD20 than rituximab and ofatumumab[1]

体内研究
(In Vivo)

Obinutuzumab is more active than rituximab administered at similar doses on established RL tumors. The antitumor effect of obinutuzumab against RL xenografts is dose dependent in terms of tumor growth inhibition (TGI). TGI is calculated using NCI formula at day 34 and shows values of 25, 75, and 85% for the 10, 30, and 100 mg/kg dosages of obinutuzumab, respectively. The higher doses of 30 and 100 mg/kg of obinutuzumab significantly inhibit the growth of RL tumors and result in some complete tumor remissions (10% and 30%, respectively). Tolerability of obinutuzumab with these regimens is excellent and no significant modification of body weight is observed[2]. Obinutuzumab induces a strong antitumor effect, including complete tumor remission in the SU-DHL4 model and overall superior efficacy compared with both rituximab and ofatumumab[1]. Obinutuzumab plus bendamustine achieves superior tumor growth inhibition versus rituximab plus bendamustine and shows a statistically significant effect versus the respective single treatments. Obinutuzumab plus chemotherapy is superior to the respective monotherapies[3].

Clinical Trial
分子量

146298.97

性状

Liquid

CAS 号

949142-50-1

中文名称

奥滨尤妥珠单抗;阿托珠单抗

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.